Petersdorf E, McKallor C, Malkki M, Hsu K, He M, Spellman S
Transplant Cell Ther. 2025; 31(3):137-156.
PMID: 39798802
PMC: 11875940.
DOI: 10.1016/j.jtct.2025.01.004.
Rodriguez-Valbuena H, Salcedo J, De Their O, Flot J, Tiozzo S, De Tomaso A
bioRxiv. 2024; .
PMID: 39463968
PMC: 11507803.
DOI: 10.1101/2024.10.16.618699.
Hadjis A, McCurdy S
Front Immunol. 2024; 15:1358668.
PMID: 38817602
PMC: 11137201.
DOI: 10.3389/fimmu.2024.1358668.
Bernit E, Jean E, Marlot B, Laget L, Izard C, Dettori I
Int J Mol Sci. 2023; 24(17).
PMID: 37686397
PMC: 10487752.
DOI: 10.3390/ijms241713591.
Ligotti M, Aiello A, Accardi G, Calabro A, Ciaccio M, Colomba C
Int J Mol Sci. 2022; 23(24).
PMID: 36555106
PMC: 9779783.
DOI: 10.3390/ijms232415466.
Graft-Versus-Solid-Tumor Effect: From Hematopoietic Stem Cell Transplantation to Adoptive Cell Therapies.
Barisic S, Childs R
Stem Cells. 2022; 40(6):556-563.
PMID: 35325242
PMC: 9216497.
DOI: 10.1093/stmcls/sxac021.
HLA-C and KIR permutations influence chronic obstructive pulmonary disease risk.
Mkorombindo T, Tran-Nguyen T, Yuan K, Zhang Y, Xue J, Criner G
JCI Insight. 2021; 6(19).
PMID: 34464355
PMC: 8525585.
DOI: 10.1172/jci.insight.150187.
The Genetic Mechanisms Driving Diversification of the Gene Cluster in Primates.
Bruijnesteijn J, de Groot N, Bontrop R
Front Immunol. 2020; 11:582804.
PMID: 33013938
PMC: 7516082.
DOI: 10.3389/fimmu.2020.582804.
Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer Immunotherapy.
Lupo K, Matosevic S
Cancers (Basel). 2019; 11(6).
PMID: 31163679
PMC: 6628161.
DOI: 10.3390/cancers11060769.
Natural killer cells: From surface receptors to the cure of high-risk leukemia (Ceppellini Lecture).
Falco M, Pende D, Munari E, Vacca P, Mingari M, Moretta L
HLA. 2019; 93(4):185-194.
PMID: 30828978
PMC: 6767140.
DOI: 10.1111/tan.13509.
Role of Immunogenetics in the Outcome of HCMV Infection: Implications for Ageing.
Aiello A, Accardi G, Candore G, Caruso C, Colomba C, Di Bona D
Int J Mol Sci. 2019; 20(3).
PMID: 30764515
PMC: 6386818.
DOI: 10.3390/ijms20030685.
Glioblastoma Stem-Like Cells Are More Susceptible Than Differentiated Cells to Natural Killer Cell Lysis Mediated Through Killer Immunoglobulin-Like Receptors-Human Leukocyte Antigen Ligand Mismatch and Activation Receptor-Ligand Interactions.
Haspels H, Rahman M, Joseph J, Gras Navarro A, Chekenya M
Front Immunol. 2018; 9:1345.
PMID: 29967607
PMC: 6015895.
DOI: 10.3389/fimmu.2018.01345.
NK cell therapy for hematologic malignancies.
Mehta R, Randolph B, Daher M, Rezvani K
Int J Hematol. 2018; 107(3):262-270.
PMID: 29383623
DOI: 10.1007/s12185-018-2407-5.
Association of maternal KIR gene content polymorphisms with reduction in perinatal transmission of HIV-1.
Omosun Y, Blackstock A, Williamson J, van Eijk A, Ayisi J, Otieno J
PLoS One. 2018; 13(1):e0191733.
PMID: 29360870
PMC: 5779696.
DOI: 10.1371/journal.pone.0191733.
Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs.
Pittari G, Vago L, Festuccia M, Bonini C, Mudawi D, Giaccone L
Front Immunol. 2017; 8:1444.
PMID: 29163516
PMC: 5682004.
DOI: 10.3389/fimmu.2017.01444.
Killer Immunoglobulin-Like Receptor Allele Determination Using Next-Generation Sequencing Technology.
Maniangou B, Legrand N, Alizadeh M, Guyet U, Willem C, David G
Front Immunol. 2017; 8:547.
PMID: 28579987
PMC: 5437120.
DOI: 10.3389/fimmu.2017.00547.
Improved full-length killer cell immunoglobulin-like receptor transcript discovery in Mauritian cynomolgus macaques.
Prall T, Graham M, Karl J, Wiseman R, Ericsen A, Raveendran M
Immunogenetics. 2017; 69(5):325-339.
PMID: 28343239
PMC: 5856007.
DOI: 10.1007/s00251-017-0977-7.
Reduction of Relapse after Unrelated Donor Stem Cell Transplantation by KIR-Based Graft Selection.
Heidenreich S, Kroger N
Front Immunol. 2017; 8:41.
PMID: 28228753
PMC: 5296332.
DOI: 10.3389/fimmu.2017.00041.
Cancer treatment and the KIR-HLA system: an overview.
Leone P, De Re V, Vacca A, Dammacco F, Racanelli V
Clin Exp Med. 2017; 17(4):419-429.
PMID: 28188495
DOI: 10.1007/s10238-017-0455-4.
NKG2A-Expressing Natural Killer Cells Dominate the Response to Autologous Lymphoblastoid Cells Infected with Epstein-Barr Virus.
Hatton O, Strauss-Albee D, Zhao N, Haggadone M, Pelpola J, Krams S
Front Immunol. 2016; 7:607.
PMID: 28018364
PMC: 5156658.
DOI: 10.3389/fimmu.2016.00607.